Weil Advises Abbott in Approximately $21 Billion Acquisition of Exact Sciences

Weil acted as antitrust counsel to Abbott Laboratories in its proposed acquisition of Exact Sciences. Abbott Laboratories, a global leader in diagnostics, medical devices, nutrition and branded generic pharmaceuticals, is acquiring Exact Sciences, a company focused on cancer screening and precision oncology diagnostics, in a transaction valued at approximately $21 billion. The transaction is expected to close in the second quarter of 2026. Weil represented client Abbott Laboratories with a team composed by: Antitrust partners Kristin Sanford, John Scribner and Michael Moiseyev; counsel Carla Hine; and associates Kathryn Graham, Megy Appalaraju, Danielle Norgren, Daniel Choi and Rahul Ramesh.

Weil Advises Abbott in Approximately $21 Billion Acquisition of Exact Sciences

Read the full story

Cookie Preferences

Strictly Necessary

Analytics & Statistics

Marketing & Ads